Skip to Content

Your Journey Starts Here,

BIOPHARMA DEVELOPMENT 

& PRODUCTION !


  • As the BioPharma industry grows in China & the Asian region, we invite you to be a part of this tremendous investment & development opportunities!
  • IBC’s Biopharma Development & Production Week in China is the meeting place for biopharma industry professionals to get the highest quality and practical information that will enable competitive edges and advance capabilities in developing and manufacturing cell lines, biosimilars, biobetters, or biologics.

​ 2 CONFERENCES IN 1 LOCATION 

MEET OVER 150 INDUSTRY ATTENDEES !​

The Region’s ONLY Cell Line Development Conference 

  • Hear from and personally meet cell line development experts as they provide latest updates and technologies
  • Learn from case studies presented by leading scientists from biopharma, research institutes and biotechs 
  • Review the latest available technologies, products and suppliers to discuss cost effective and quality process development
  • Hear cutting edge technology in single use biomanufacturing systems

Why You Must Attend in 2015 !

-Learn technical & practical know how from experiences on the ground in China & Asia.

-Establish Business Partnerships with Chinese/Asian drug developers and contract manufacturers.

-Meet with 70+ C-Level Biopharma Asia Expert Speakers.

-Showcase your cutting edge solutions in front of key China/Asian Biopharma decision makers.

-Speed Networking to get to know your industry peers.

-Interactive Pre & Post Workshops for detailed & practical development.

What to Expect at the Biopharma Development & Production Week in China !

320+ attendees across the biopharma value chain

4+ days of value packed information & knowledge sharing

70+ expert biopharma speakers to hear from

3 conferences under one roof

15+ different ways for you to get to know your industry peers

1 Joint networking & exhibition area

2015 Speakers include :

  • Dr. Elena Marquez, Global Head of Oncology Innovation, BioGenix Therapeutics, Spain
  • Wei (Victor) Zhang, Chief Strategy Officer, Global Operations, Shanghai BioPharma Solutions, China
  • Ravi Kapoor, Senior Vice President – Biosimilars Division, ViroCell Biologics, India
  • Dr. Min-Ji Park, Vice President of Clinical Development, CellVax Therapeutics, South Korea
  • Anika Patel, President – Biotech Division, Zylox Pharmaceuticals, India
  • Dr. Sophia Reinhardt, Global Clinical Lead, Oncology & Biotherapeutics, RocheBio Innovations, Germany
  • Sean O’Donnell, Executive Director, International Quality & Compliance, JAPAC Region, AmgenX, Singapore
  • Lars Fischer, Executive Director of Upstream Manufacturing & Technology Transfer, BioIngen Solutions, Germany
  • Xiao (Leo) Chen, Senior Vice President, Global Operations & Bio Ventures, AstraBio Therapeutics, China
  • Dr. Mei Ling, Chairman & CEO, AkesoBio Sciences, China
  • Ying (Grace) Li, Executive Vice President, Quality & Regulatory Affairs, AlphaBio Innovations, China
  • Jian (Alex) Wu, CEO, Wuhan BioCell Therapeutics, China
  • Dr. Xiang (David) Liu, CEO, HuaXin Biopharma, China
  • Scott Zhang, CEO, HenXin Pharmaceuticals, USA
  • Dr. Li (Amy) Wang, Vice President of R&D, Beijing BioWorks, China
  • Peng (Leo) Zhao, President of R&D, Yabao BioPharma Group, China
  • Dr. Wei (Jason) Lin, Senior Director, Cell Culture & Process Development, LivBio Therapeutics, China
  • Dr. Emily Chen, Principal Scientist, MerckBio Innovations, USA